Generation Bio set for worst day after hemophilia A study update

Generation Bio

14/12/2021 13:44

** Shares of gene therapy developer  GBIO.O  fall ~29% to
$9.90 premarket, set for worst day
    ** Co reports data from mice and non-human primate (NHP)
studies in hemophilia A (https://refini.tv/3m3jEMs)
    ** Hemophilia A is a hereditary bleeding disorder caused by
a subnormal levels of blood clotting protein called factor VIII
    ** Co's closed-ended DNA delivered via a cell-targeted lipid
nanoparticle generated peak mean human factor VIII expression of
205% in mice, non-human primates demonstrated up to 2% normal
human factor VIII expression
    ** Additional optimization is needed to translate the
improvement in potency and reduction in variability observed in
mice to NHP, and to support nomination of a development
candidate for co's hemophilia A program - GBIO

 (Reporting by Mrinalika Roy in Bengaluru)
 ((mrinalika.roy@thomsonreuters.com; within U.S. +1 646 223
8780, outside U.S. +91 806749 8325;))